Evonik is investing approximately EUR 80 million to expand its biotechnology capabilities at its Fermas site in Slovenská Ľupča, Slovakia. The investment will add state-of-the-art downstream fermentation technology to support the contract manufacturing services of the group’s drug substance business. The expansion will create approximately 50 new jobs at the site.
“With demand for complex pharmaceutical ingredients continuing to rise, our enhanced biotechnology capabilities will enable us to support customers with reliable, scalable, and sustainable production,” said Guido Skudlarek, head of the Health Care business line.
This investment is the second major financial commitment at the Fermas site in recent years, following the construction of Evonik’s rhamnolipids plant, initiated in 2022. The site continues to expand its capacity for biofermentation scale-up and downstream processing, reinforcing its position as a hub for advanced biotechnological production.
In 2024, Evonik became the first company worldwide to produce industrial-scale rhamnolipid biosurfactants, marking a milestone in sustainable specialty chemicals.
